{"id":13871,"date":"2019-08-19T11:56:53","date_gmt":"2019-08-19T03:56:53","guid":{"rendered":"https:\/\/id-ea.org\/tbe\/?p=13871"},"modified":"2019-08-19T17:42:21","modified_gmt":"2019-08-19T09:42:21","slug":"snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/","title":{"rendered":"Snapshot week 34\/2019<br> Long-term TBE vaccine induced antibody persistence"},"content":{"rendered":"<span class=\"cb-itemprop\" itemprop=\"reviewBody\"><p>Beran et al.<br \/>\nSecond five-year follow-up after booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence.<br \/>\n<em>Vaccine<\/em> 2019, 27: 4623-4629<\/p>\n<p>In a clinical trial, for the TBE vaccine based on strain K23 (European subtype) using various primary immunization schedules in adolescents and adults (conventional, accelerated conventional, modified conventional and rapid), it had been shown that the antibodies persist at least for five years after the first booster dose. In an extension study, the antibody persistence was now evaluated from six up to ten years post-last vaccination. While the lowest limit of detection for neutralizing antibodies was a titer of 2, NT titers of at least 10 were considered a clinical meaningful threshold. Of 206 screened individuals, 201 were enrolled and 191 completed the study. At all timepoints, all individuals (with two exceptions) had a NT of \u22652 as well as \u226510. The percentage of participants with NT titers of \u226510 were \u226598% in the per-protocol set in each of the groups (15-49 years, \u226550 years, \u226560 years) and the percentage of vaccinees with NT titers \u226510 across all timepoints did not seem to differ with age. Overall, GMTs remained similar across groups. NT GMTs seemed to decrease with increasing age but remained similar within the same age strata at each timepoint. These results confirm the long-term persistence of immune response against the strain K23 based TBE virus vaccine following a booster dose and the antibody persistence was independent from the primary immunization schedule as measured by the participants with NT titers above a chosen clinically meaningful threshold.<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"<p>Beran et al. Second five-year follow-up after booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence. Vaccine 2019, 27: 4623-4629 In a clinical trial, for the TBE vaccine based on strain K23 (European subtype) using various primary immunization schedules in adolescents and adults (conventional, accelerated conventional, modified conventional and rapid), it had been shown that the antibodies persist at least for five years after the first booster dose. In an extension study, the antibody persistence was now evaluated from six up to ten years post-last vaccination. While the lowest limit of detection for neutralizing antibodies was a titer of 2, NT titers of at least 10 were considered a clinical meaningful threshold. Of 206 screened individuals, 201 were enrolled and 191 completed the study. At all timepoints, all individuals (with two exceptions) had a NT of \u22652 as well as \u226510. The percentage of participants with NT titers of \u226510 were \u226598% in the per-protocol set in each of the groups (15-49 years, \u226550 years, \u226560 years) and the percentage of vaccinees with NT titers \u226510 across all timepoints did not seem to differ with age. Overall, GMTs remained similar across groups. NT GMTs seemed to decrease with increasing age but remained similar within the same age strata at each timepoint. These results confirm the long-term persistence of immune response against the strain K23 based TBE virus vaccine following a booster dose and the antibody persistence was independent from the primary immunization schedule as measured by the participants with NT titers above a chosen clinically meaningful threshold.<\/p>\n","protected":false},"author":6,"featured_media":12864,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18],"tags":[298,294,295,293,249],"coauthors":[81],"class_list":["post-13871","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot","tag-accelerated-conventional","tag-antibody-persistence","tag-booster-vaccination","tag-clinical-trial","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Snapshot week 34\/2019 Long-term TBE vaccine induced antibody persistence - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot week 34\/2019 Long-term TBE vaccine induced antibody persistence - TBE Book\" \/>\n<meta property=\"og:description\" content=\"Beran et al. Second five-year follow-up after booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence. Vaccine 2019, 27: 4623-4629 In a clinical trial, for the TBE vaccine based on strain K23 (European subtype) using various primary immunization schedules in adolescents and adults (conventional, accelerated conventional, modified conventional and rapid), it had been shown that the antibodies persist at least for five years after the first booster dose. In an extension study, the antibody persistence was now evaluated from six up to ten years post-last vaccination. While the lowest limit of detection for neutralizing antibodies was a titer of 2, NT titers of at least 10 were considered a clinical meaningful threshold. Of 206 screened individuals, 201 were enrolled and 191 completed the study. At all timepoints, all individuals (with two exceptions) had a NT of \u22652 as well as \u226510. The percentage of participants with NT titers of \u226510 were \u226598% in the per-protocol set in each of the groups (15-49 years, \u226550 years, \u226560 years) and the percentage of vaccinees with NT titers \u226510 across all timepoints did not seem to differ with age. Overall, GMTs remained similar across groups. NT GMTs seemed to decrease with increasing age but remained similar within the same age strata at each timepoint. These results confirm the long-term persistence of immune response against the strain K23 based TBE virus vaccine following a booster dose and the antibody persistence was independent from the primary immunization schedule as measured by the participants with NT titers above a chosen clinically meaningful threshold.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2019-08-19T03:56:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-08-19T09:42:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Michael Br\u00f6ker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Br\u00f6ker\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/\"},\"author\":{\"name\":\"augustine\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2f903afeb7534df7457d2e3f6d30f64c\"},\"headline\":\"Snapshot week 34\\\/2019 Long-term TBE vaccine induced antibody persistence\",\"datePublished\":\"2019-08-19T03:56:53+00:00\",\"dateModified\":\"2019-08-19T09:42:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/\"},\"wordCount\":258,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"keywords\":[\"accelerated conventional\",\"antibody persistence\",\"booster vaccination\",\"clinical trial\",\"vaccine\"],\"articleSection\":[\"Snapshot\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/\",\"name\":\"Snapshot week 34\\\/2019 Long-term TBE vaccine induced antibody persistence - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2019-08-19T03:56:53+00:00\",\"dateModified\":\"2019-08-19T09:42:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot week 34\\\/2019 Long-term TBE vaccine induced antibody persistence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2f903afeb7534df7457d2e3f6d30f64c\",\"name\":\"augustine\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=ge035e25b3672069f7222fdb9b71e7000\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g\",\"caption\":\"augustine\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/augustine-augustine\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot week 34\/2019 Long-term TBE vaccine induced antibody persistence - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot week 34\/2019 Long-term TBE vaccine induced antibody persistence - TBE Book","og_description":"Beran et al. Second five-year follow-up after booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence. Vaccine 2019, 27: 4623-4629 In a clinical trial, for the TBE vaccine based on strain K23 (European subtype) using various primary immunization schedules in adolescents and adults (conventional, accelerated conventional, modified conventional and rapid), it had been shown that the antibodies persist at least for five years after the first booster dose. In an extension study, the antibody persistence was now evaluated from six up to ten years post-last vaccination. While the lowest limit of detection for neutralizing antibodies was a titer of 2, NT titers of at least 10 were considered a clinical meaningful threshold. Of 206 screened individuals, 201 were enrolled and 191 completed the study. At all timepoints, all individuals (with two exceptions) had a NT of \u22652 as well as \u226510. The percentage of participants with NT titers of \u226510 were \u226598% in the per-protocol set in each of the groups (15-49 years, \u226550 years, \u226560 years) and the percentage of vaccinees with NT titers \u226510 across all timepoints did not seem to differ with age. Overall, GMTs remained similar across groups. NT GMTs seemed to decrease with increasing age but remained similar within the same age strata at each timepoint. These results confirm the long-term persistence of immune response against the strain K23 based TBE virus vaccine following a booster dose and the antibody persistence was independent from the primary immunization schedule as measured by the participants with NT titers above a chosen clinically meaningful threshold.","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/","og_site_name":"TBE Book","article_published_time":"2019-08-19T03:56:53+00:00","article_modified_time":"2019-08-19T09:42:21+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"Michael Br\u00f6ker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Michael Br\u00f6ker","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/"},"author":{"name":"augustine","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2f903afeb7534df7457d2e3f6d30f64c"},"headline":"Snapshot week 34\/2019 Long-term TBE vaccine induced antibody persistence","datePublished":"2019-08-19T03:56:53+00:00","dateModified":"2019-08-19T09:42:21+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/"},"wordCount":258,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","keywords":["accelerated conventional","antibody persistence","booster vaccination","clinical trial","vaccine"],"articleSection":["Snapshot"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/","name":"Snapshot week 34\/2019 Long-term TBE vaccine induced antibody persistence - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","datePublished":"2019-08-19T03:56:53+00:00","dateModified":"2019-08-19T09:42:21+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-34-2019-long-term-tbe-vaccine-induced-antibody-persistence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot week 34\/2019 Long-term TBE vaccine induced antibody persistence"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2f903afeb7534df7457d2e3f6d30f64c","name":"augustine","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=ge035e25b3672069f7222fdb9b71e7000","url":"https:\/\/secure.gravatar.com\/avatar\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g","caption":"augustine"},"url":"https:\/\/tbenews.com\/tbe\/author\/augustine-augustine\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/13871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=13871"}],"version-history":[{"count":2,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/13871\/revisions"}],"predecessor-version":[{"id":13873,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/13871\/revisions\/13873"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/12864"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=13871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=13871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=13871"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=13871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}